论文部分内容阅读
目的:评估预激(CAEG)方案对难治、复发性急性非淋巴细胞白血病(ANLL)且不能耐受大剂量化疗患者的疗效。方法:予小剂量阿糖胞苷(Ara-C,10mg/m2/d,第1天~第14天,每12h皮下注射)、阿克拉霉素(Acla20mg/d,第1天~第4天,静脉输注)、足叶乙甙(VP1650mg/d,第1天~第4天,静脉注射)、粒细胞集落刺激因子(G-CSF100μg/m2/d~200μg/m2/d,第1天~第14天,皮下注射)在内的CAEG方案治疗难治、复发性ANLL18例。结果:8例(44.4%)患者取得完全缓解(CR),5例(27.7%)获部分缓解(PR),总有效率72.1%。可见粒细胞缺乏、血小板减少、继发感染及发热等不良反应,无严重不良反应。结论:预激方案治疗难治、复发性ANLL疗效较好,毒副反应轻。
OBJECTIVE: To evaluate the efficacy of the pro-excitation (CAEG) regimen in patients refractory to recurrent acute non-lymphocytic leukemia (ANLL) who are refractory to high-dose chemotherapy. Methods: A small dose of cytarabine (Ara-C, 10mg / m2 / d, day 1 to day 14, subcutaneous injection every 12h), aclacinomycin (Acla20mg / d, the first day to the fourth day , Intravenous infusion), etoposide (VP1650mg / d, day 1 to day 4, intravenous injection), granulocyte colony stimulating factor (G-CSF100μg / m2 / d ~ 200μg / m2 / d, ~ 14 days, subcutaneous injection), including CAEG regimen refractory, recurrent ANLL18 cases. Results: Complete remission (CR) was achieved in 8 patients (44.4%) and partial response (PR) in 5 patients (27.7%), with a total effective rate of 72.1%. Can be seen agranulocytosis, thrombocytopenia, secondary infection and fever and other adverse reactions, no serious adverse reactions. Conclusion: The pre-excitation regimen is refractory to recurrent ANLL with good side effects.